Table 1.
The patient characteristics of the 53 patients who were analyzed for the main part of the study (Figures 1–4).
| cGVHD | None | Mild | Moderate | Severe |
|---|---|---|---|---|
| n | 17 | 13 | 12 | 11 |
| Age [median (range)] | ||||
| Patient | 50 (34–71) | 51 (30–65) | 53 (29–63) | 39 (15–60) |
| Donor | 29 (22–72) | 34 (18–58) | 46 (30–63) | 35 (17–62) |
| Gender (male/female) | ||||
| Patient | 10/7 | 5/8 | 8/4 | 7/4 |
| Donor | 11/6 | 4/9 | 7/5 | 5/6 |
| Stem cell source | ||||
| BM | 0 | 1 | 1 | 2 |
| PBSC | 16 | 11 | 11 | 9 |
| BM + PBSC | 1 | 1 | 0 | 0 |
| Matching | ||||
| Sibling/unrelated/haplo | 7/10/0 | 2/10/1 | 9/3/0 | 7/4/0 |
| Diagnosis | ||||
| Solid tumor | 1 | 1 | 0 | 1 |
| AML | 6 | 9 | 3 | 4 |
| ALL | 2 | 2 | 2 | 1 |
| MDS/MPS | 4 | 1 | 2 | 3 |
| MM | 0 | 0 | 1 | 0 |
| CML | 0 | 0 | 1 | 0 |
| CLL | 1 | 0 | 1 | 0 |
| Lymphoma | 3 | 0 | 2 | 2 |
| Prophylaxis | ||||
| CsA + MTX | 11 | 10 | 10 | 7 |
| Tac + Sir | 5 | 2 | 2 | 4 |
| PTCy | 1 | 1 | 0 | 0 |
| Conditioning | ||||
| RIC/MAC | 14/3 | 10/3 | 7/5 | 5/6 |
| Anti T-cell antibody treatment | ||||
| Yes/no | 10/7 | 10/3 | 3/9 | 5/6 |
| aGVHD | ||||
| None/I/II/III | 11/4/2/0 | 7/3/2/1 | 2/2/6/2 | 2/2/3/4 |
| Systemic immunosuppressive treatment at inclusion | ||||
| Yes/no | 2/15 | 6/7 | 12/0 | 10/1 |
cGVHD, chronic graft-versus-host disease; n, number; BM, bone marrow; PBSCs, peripheral blood stem cells; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; MPS, myeloproliferative syndrome; MM, multiple myeloma; CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; CsA, cyclosporine; MTX, methotrexate; Tac, tacrolimus; Sir, sirolimus; PTCy, posttransplant cyclophosphamide; RIC, reduced intensity conditioning; MAC, myeloablative conditioning; aGVHD, acute graft-versus-host disease.